Open-label non-controlled study to examine the safety and efficacy of long-term administration of KRP-114V intended for overactive bladder patients
Phase of Trial: Phase III
Latest Information Update: 07 Nov 2017
At a glance
- Drugs Vibegron (Primary)
- Indications Overactive bladder
- Focus Adverse reactions; Registrational
- Sponsors Kyorin Pharmaceutical
- 06 Nov 2017 Status changed from active, no longer recruiting to completed.
- 28 Dec 2015 New trial record
- 05 Nov 2015 Status changed from recruiting to active, no longer recruiting.